Norethindrone (Norethisterone)

A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for contraception.

Also Known As:

Networked: 284 relevant articles (16 outcomes, 46 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Mueck, Alfred O: 5 articles (05/2013 - 07/2002)
2.	Seeger, Harald: 4 articles (05/2013 - 07/2002)
3.	Lidegaard, Øjvind: 3 articles (10/2014 - 01/2009)
4.	Seeger, H: 3 articles (01/2006 - 11/2001)
5.	Mueck, A O: 3 articles (01/2006 - 11/2001)
6.	Wallwiener, D: 3 articles (01/2006 - 11/2001)
7.	Wallwiener, Diethelm: 3 articles (07/2005 - 07/2002)
8.	Liang, Yayun: 2 articles (05/2013 - 09/2010)
9.	Hyder, Salman M: 2 articles (05/2013 - 09/2010)
10.	Løkkegaard, Ellen: 2 articles (06/2012 - 01/2009)

Related Diseases

1.	Hemorrhage 02/01/2014 - "Twenty patients required norethindrone taper for heavy bleeding; of this group 78.9% experienced complete cessation of bleeding within 7 days. " 02/01/2014 - "Our objectives were to review norethindrone use in an adolescent population in a tertiary care center and to assess the effectiveness of the norethindrone taper in the management of acute heavy menstrual bleeding in adolescents. " 03/01/2010 - "A withdrawal bleed within a few days of stopping the norethisterone indicates the presence of oestrogen and bleeding more than a few drops is considered a positive withdrawal bleed. " 02/01/1995 - "If the endometrial thickness on the onset of progestogen addition was 5 mm or more, in nearly all cases withdrawal bleeding occurred when MPA or norethisterone was used. " 11/01/1980 - "Effect of norethisterone on puerperal vaginal bleeding."
2.	Endometriosis (Adenomyosis) 08/01/1992 - "The role of norethindrone as a supplement to GnRHa in eliminating such side effects was assessed by enrolling 20 patients with symptomatic endometriosis diagnosed laparoscopically in a randomized, prospective, double-blinded trial. " 01/01/1964 - "CELIOSCOPIC STUDY OF WOMEN TREATED WITH CYCLIC NORETHISTERONE FOR ENDOMETRIOSIS." 10/01/1995 - "Norethindrone is effective as add-back in the management of endometriosis but not leiomyomata, although high doses alter lipid profiles in an undesirable fashion. " 08/01/1992 - "The addition of norethindrone to GnRHa is an effective means of treating symptomatic endometriosis while ameliorating side effects induced by GnRHa alone." 08/01/2000 - "Domestic LHRH-a combined with low-dose norethindrone was effective in the treatment of endometriosis. "
3.	Menorrhagia 01/01/2015 - "She had used norethisterone to postpone her menstruation and presented to our institution with severe menorrhagia. " 04/01/2008 - "The regimen of TA 3 g daily during menstrual days 1-5 is a more effective and tolerable treatment than luteal phase norethisterone for patients with ovulatory menorrhagia." 05/01/1995 - "Norethisterone at this dose is not effective therapy for ovulatory menorrhagia." 11/01/2010 - "Continuous high-dose (10 to 20 mg/day) continuous norethisterone to treat menorrhagia in adolescents and young women with bleeding disorders is inadvisable. " 11/01/1993 - "Our purpose was to compare the efficacy of the recommended dose of danazol, a reduced-dose danazol regimen, and norethindrone in the treatment of objectively proven menorrhagia. "
4.	Hyperparathyroidism 04/01/1987 - "We conclude that norethindrone is an effective treatment for mild hyperparathyroidism in postmenopausal women." 09/01/1990 - "Treatment of postmenopausal hyperparathyroidism with norethindrone. " 04/01/1987 - "Treatment of postmenopausal hyperparathyroidism with norethindrone. " 02/01/1989 - "Norethisterone can inhibit bone resorption and has recently been shown to be effective treatment for mild hyperparathyroidism in post menopausal women. " 06/05/1986 - "To assess the effect of these sex steroids in patients with primary hyperparathyroidism, we treated postmenopausal women who had hyperparathyroidism with either ethinyl estradiol (n = 6) or norethindrone (n = 11). "
5.	Breast Neoplasms (Breast Cancer) 05/01/1993 - "Oestrogens are known to stimulate the growth of human breast cancer cells, and this laboratory has previously reported (Jeng & Jordan, 1991) that the 19-norprogestin norethindrone could stimulate the proliferation of MCF-7 human breast cancer cells. " 09/01/1982 - "Twenty-six patients with advanced breast cancer and progressive disease were treated by norethisterone. " 03/19/1968 - "[Results of norethindrone (norluten) treatment of diffusion phase breast cancer]." 01/01/1974 - "18 French women with bone metastases of breast cancer were treated with norethisterone 60 mg per day (except 1 woman given 20 mg daily) for 2 months or until the end of the remission from 1969-1972. " 05/01/2013 - "Clinical trials have demonstrated an increased risk of breast cancer during estrogen/norethisterone (NET) therapy. "

Related Drugs and Biologics

1.	Levonorgestrel (Plan B)
2.	Ethinyl Estradiol (Estinyl)
3.	Gonadotropin-Releasing Hormone (GnRH)
4.	estradiol valerate (Delestrogen)
5.	Nafarelin (Synarel)
6.	Tranexamic Acid (AMCA)
7.	Mefenamic Acid (Pontal)
8.	Danazol (Azol)
9.	NuvaRing
10.	Iron

Related Therapies and Procedures

1.	Intrauterine Devices (Intrauterine Device)
2.	Female Contraceptive Devices (Vaginal Ring)
3.	Platelet Transfusion (Blood Platelet Transfusions)
4.	Injections
5.	Contraception (Birth Control)